<DOC>
	<DOCNO>NCT02700984</DOCNO>
	<brief_summary>This observational study involve patient complete COMPASS Trial , CyPass Micro-Stent evaluate 2 year postoperatively . In COMPASS-XT study , clinical data collect participate subject additional 3 year .</brief_summary>
	<brief_title>A Study Assess Long-Term Safety CyPass Micro-Stent Patients Completing COMPASS Trial</brief_title>
	<detailed_description>The COMPASS Trial prospective , randomize , comparative multicenter study assess safety effectiveness CyPass Micro-Stent subject primary open angle glaucoma undergo cataract surgery . In study , 505 subject randomize either CyPass group , underwent cataract surgery receive CyPass Micro-Stent , Control group , underwent cataract surgery alone . All subject randomize follow 2 year postoperatively . Four hundred eighty ( 480 ) subject complete study . The COMPASS-XT Trial design collect safety data beyond 24 month postoperatively subject complete COMPASS Trial . In COMPASS-XT , clinical data collect 3 , 4 5 year postoperatively total 5 year follow-up across 2 study .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<criteria>1 . Completed COMPASS Trial 2 . Understands study requirement willing follow study instruction return study visit 1 . Systemic disease would put subject health risk and/or prevent completion require study visit . 2 . Early termination COMPASS Trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>